Apelin hormone injections powerfully lower blood sugar

Nov 04, 2008

By injecting a hormone produced by fat and other tissues into mice, researchers report in the November Cell Metabolism that they significantly lowered blood sugar levels in normal and obese mice. The findings suggest that the hormone known as apelin might be a promising target for managing insulin resistance and type 2 diabetes.

Insulin resistance, in which normal amounts of insulin are insufficient to lower blood sugar (glucose) levels, is a precursor to diabetes.

" The effects of apelin appear to be similar to insulin," although they operate in different ways, said Isabelle Castan-Laurell of Institut National de la Santé et de la Recherche Médicale and Université de Toulouse.

Earlier studies had suggested a link between apelin and insulin, Castan-Laurell said. Apelin levels were shown to parallel insulin levels in mice and humans. Apelin levels in the blood also rise in those who are obese and in those with type 2 diabetes.

Those findings led the researchers to suspect that apelin and insulin might have other similarities.

Now, they show that acute intravenous injections of apelin have a powerful blood sugar-lowering effect on mice. They also show evidence that apelin stimulates muscle and fat tissue to take up glucose from the bloodstream by stimulating a known glucose transport pathway. Specifically, apelin activates a pathway including an enzyme called AMP-activated protein kinase (AMPK), which plays a pivotal role in the control of skeletal muscle glucose and the metabolism of fatty acids.

Moreover, they showed that apelin treatment restores glucose tolerance and improves glucose uptake in mice that are obese and insulin resistant.

Castan-Laurell said they aren't quite sure yet what it means that obese individuals tend to have high apelin levels. It could be that apelin levels don't rise enough to curb rising blood sugar or perhaps insulin resistance without apelin would be even worse. Alternatively, obese animals and humans might grow resistant to the action of apelin just as they do insulin.

The researchers said they will now examine the effects of chronic apelin treatment in the mice to see if the hormone can ward of obesity and insulin resistance in the longer term.

" In conclusion," the researchers wrote, "the present study reveals apelin as a new endocrine regulator of AMPK and strengthens the crosstalk between [fat] and skeletal muscle. The involvement of AMPK in apelin-mediated glucose uptake represents an attractive pathway that could conceivably lead to a new drug target for the treatment of metabolic disorders."

Either way, they added, the discovery offers new insights into the physiology of glucose and lipid metabolism in health and disease.

Source: Cell Press

Explore further: Scottish zoo: 'Bad news' for pregnant giant panda

add to favorites email to friend print save as pdf

Related Stories

Scientists get set for simulated nuclear inspection

15 hours ago

Some 40 scientists and technicians from around the world will descend on Jordan in November to take part in a simulated on-site inspection of a suspected nuclear test site on the banks of the Dead Sea.

Alibaba IPO comes with unusual structure

15 hours ago

Foreigners who want to buy Alibaba Group shares in the Chinese e-commerce giant's U.S. public offering will need to get comfortable with an unusual business structure.

Recommended for you

DNA may have had humble beginnings as nutrient carrier

9 hours ago

New research intriguingly suggests that DNA, the genetic information carrier for humans and other complex life, might have had a rather humbler origin. In some microbes, a study shows, DNA pulls double duty ...

Central biobank for drug research

9 hours ago

For the development of new drugs it is crucial to work with stem cells, as these allow scientists to study the effects of new active pharmaceutical ingredients. But it has always been difficult to derive ...

No-take marine reserves a no-win for seahorses

10 hours ago

A UTS study on how seahorses are faring in no-take marine protected areas (MPAs) in NSW has revealed that where finishing is prohibited, seahorses aren't doing as well.

User comments : 0